Company Profile
Biomea Fusion Stock Price, News & Analysis
- Ticker:
- BMEA
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- United States
Stock performance
1.33 USD (+0.76%)
Close
Last updated: July 13, 2026 at 00:00
95.44M USD
Market cap
Why the stock is moving
BMEA is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Biomea Fusion is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Biomea Fusion is followed within the biotech universe for its exposure to catalyst-driven execution.
Business Model Characteristics
Biomea Fusion follows a catalyst-driven model where the market watches how the company turns development work into repeatable value creation.
Position Within the Biotechnology Landscape
Compared with more mature healthcare peers, Biomea Fusion sits closer to the development side of the biotechnology landscape, where timing around data and approvals matters most.
Future catalysts
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
Zimmer Biomet Names Chintan Desai President of Asia Pacific Region
ZBH · Source: Zimmer Biomet
- 02
Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results
ZBH · Source: Zimmer Biomet
- 03
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
BMY · Source: BMYBristol-Myers Squibb Company
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Biomea Fusion (BMEA)?
Biomea Fusion (BMEA) most recently closed at 1.33 USD, a +0.76% move versus the previous session.
What is the market cap of Biomea Fusion (BMEA)?
Biomea Fusion currently has a market capitalization of 95.44M USD on BioPharmSignal.
What does Biomea Fusion do?
Biomea Fusion is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
On which exchange is BMEA stock listed?
Biomea Fusion (BMEA) is associated with NASDAQ, United States, Biotechnology.
What is Biomea?
Biomea Fusion is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs.
Which conditions is Biomea Fusion targeting with Biomea?
Biomea Fusion is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
What is Fusion?
Biomea Fusion is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs.
What is Investors?
Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.